JP6781806B2 - Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 - Google Patents

Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 Download PDF

Info

Publication number
JP6781806B2
JP6781806B2 JP2019123100A JP2019123100A JP6781806B2 JP 6781806 B2 JP6781806 B2 JP 6781806B2 JP 2019123100 A JP2019123100 A JP 2019123100A JP 2019123100 A JP2019123100 A JP 2019123100A JP 6781806 B2 JP6781806 B2 JP 6781806B2
Authority
JP
Japan
Prior art keywords
alkyl
methyl
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019123100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020002135A (ja
Inventor
イー．アール． シラー ショーン
イー．アール． シラー ショーン
ハーバーツ トルステン
ハーバーツ トルステン
リー ホンビン
リー ホンビン
グレイブス ブラッドフォード
グレイブス ブラッドフォード
ミシュケ スティーブン
ミシュケ スティーブン
ブイ． ウエスト アンジェラ
ブイ． ウエスト アンジェラ
エリクソン アンナ
エリクソン アンナ
アール． ダウニング ジェニファー
アール． ダウニング ジェニファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of JP2020002135A publication Critical patent/JP2020002135A/ja
Application granted granted Critical
Publication of JP6781806B2 publication Critical patent/JP6781806B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019123100A 2018-06-29 2019-07-01 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害 Active JP6781806B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
US62/692,593 2018-06-29
WOPCT/US2018/051235 2018-09-14
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WOPCT/US2018/051214 2018-09-14
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US201962819490P 2019-03-15 2019-03-15
US62/819,490 2019-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020093126A Division JP7017801B2 (ja) 2018-06-29 2020-05-28 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害

Publications (2)

Publication Number Publication Date
JP2020002135A JP2020002135A (ja) 2020-01-09
JP6781806B2 true JP6781806B2 (ja) 2020-11-04

Family

ID=68987627

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019123100A Active JP6781806B2 (ja) 2018-06-29 2019-07-01 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
JP2020093126A Active JP7017801B2 (ja) 2018-06-29 2020-05-28 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
JP2020209005A Withdrawn JP2021042255A (ja) 2018-06-29 2020-12-17 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
JP2025046918A Pending JP2025094157A (ja) 2018-06-29 2025-03-21 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020093126A Active JP7017801B2 (ja) 2018-06-29 2020-05-28 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
JP2020209005A Withdrawn JP2021042255A (ja) 2018-06-29 2020-12-17 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
JP2025046918A Pending JP2025094157A (ja) 2018-06-29 2025-03-21 Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害

Country Status (26)

Country Link
US (3) US10870648B2 (enExample)
EP (1) EP3998266A1 (enExample)
JP (4) JP6781806B2 (enExample)
KR (2) KR102805503B1 (enExample)
CN (2) CN112513038B (enExample)
AU (3) AU2019295790B2 (enExample)
BR (1) BR112020026783A2 (enExample)
CA (1) CA3105099A1 (enExample)
CY (1) CY1124762T1 (enExample)
DK (1) DK3587418T3 (enExample)
ES (1) ES2900105T3 (enExample)
HR (1) HRP20211698T1 (enExample)
HU (1) HUE056885T2 (enExample)
IL (3) IL279734B2 (enExample)
LT (1) LT3587418T (enExample)
MA (1) MA50675B1 (enExample)
MX (2) MX2023013508A (enExample)
PL (1) PL3587418T3 (enExample)
PT (1) PT3587418T (enExample)
RS (1) RS62732B1 (enExample)
SA (1) SA520420909B1 (enExample)
SG (1) SG11202012767UA (enExample)
SI (1) SI3587418T1 (enExample)
SM (1) SMT202100636T1 (enExample)
WO (1) WO2020006483A1 (enExample)
ZA (2) ZA202100509B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102805503B1 (ko) * 2018-06-29 2025-05-09 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
EP3938365A4 (en) * 2019-03-15 2023-01-25 Forma Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF ANDROGEN RECEPTOR POSITIVE FORMS OF CANCER
CA3184076A1 (en) 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
CN115701996B (zh) 2020-06-25 2024-12-24 托雷莫治疗股份公司 用于治疗EGFR突变型NSCLC的CBP/p300溴结构域抑制剂和EGFR抑制剂的组合
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
KR100865775B1 (ko) 2000-11-20 2008-10-29 메르크 파텐트 게엠베하 키랄 광이성질성 화합물
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (enExample) 2003-11-13 2008-10-06
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2652235A1 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
IN2014MN02330A (enExample) 2007-06-21 2015-08-14 Wistar Inst
EP2173721B1 (en) 2007-06-26 2011-12-28 Sanofi A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
US8222417B2 (en) 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
PT3289876T (pt) 2008-06-16 2022-10-28 Univ Tennessee Res Found Compostos para o tratamento do câncer
US8604030B2 (en) * 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
MX340424B (es) 2009-04-15 2016-07-08 Jw Pharmaceutical Corp Compuestos novedosos de mimeticos de cambio inverso; metodo para fabricarlos y su uso.
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
MX370535B (es) * 2013-11-18 2019-12-17 Forma Therapeutics Inc Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
CN107073125A (zh) 2014-09-19 2017-08-18 基因泰克公司 Cbp/ep300和bet抑制剂用于治疗癌症的用途
CN107531690B (zh) * 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
TWI846350B (zh) * 2017-09-15 2024-06-21 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
KR102805503B1 (ko) * 2018-06-29 2025-05-09 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해

Also Published As

Publication number Publication date
US20200002332A1 (en) 2020-01-02
PL3587418T3 (pl) 2022-02-21
ZA202210560B (en) 2025-12-17
LT3587418T (lt) 2021-11-25
AU2019295790B2 (en) 2023-07-13
MA50675B1 (fr) 2021-09-30
KR20250067962A (ko) 2025-05-15
WO2020006483A1 (en) 2020-01-02
US11254674B2 (en) 2022-02-22
KR102805503B1 (ko) 2025-05-09
IL279734B1 (en) 2024-07-01
US20220162207A1 (en) 2022-05-26
MX2020014303A (es) 2021-03-25
EP3998266A1 (en) 2022-05-18
JP2025094157A (ja) 2025-06-24
SI3587418T1 (sl) 2022-03-31
CN112513038B (zh) 2023-01-10
HRP20211698T1 (hr) 2022-02-18
IL313466B2 (en) 2025-11-01
AU2025210762A1 (en) 2025-08-21
AU2019295790A1 (en) 2021-01-28
MX2023013508A (es) 2023-12-13
IL279734B2 (en) 2024-11-01
JP2020128426A (ja) 2020-08-27
US12378242B2 (en) 2025-08-05
US20200299295A1 (en) 2020-09-24
RS62732B1 (sr) 2022-01-31
SA520420909B1 (ar) 2024-11-12
ZA202100509B (en) 2022-12-21
SMT202100636T1 (it) 2022-01-10
CA3105099A1 (en) 2020-01-02
JP7017801B2 (ja) 2022-02-09
JP2020002135A (ja) 2020-01-09
CY1124762T1 (el) 2022-07-22
JP2021042255A (ja) 2021-03-18
AU2023226653B2 (en) 2025-09-04
BR112020026783A2 (pt) 2021-03-30
IL313466B1 (en) 2025-07-01
MA50675A (fr) 2021-04-07
IL279734A (en) 2021-03-01
CN116178369A (zh) 2023-05-30
ES2900105T3 (es) 2022-03-15
US10870648B2 (en) 2020-12-22
KR20210025631A (ko) 2021-03-09
HUE056885T2 (hu) 2022-03-28
AU2023226653A1 (en) 2023-09-21
DK3587418T3 (da) 2021-10-11
SG11202012767UA (en) 2021-01-28
IL313466A (en) 2024-08-01
IL321337A (en) 2025-08-01
PT3587418T (pt) 2021-12-02
CN112513038A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
JP6781806B2 (ja) Ｃｒｅｂ結合タンパク質（ｃｂｐ）の阻害
CN115215886B (zh) 作为内体Toll样受体抑制剂的化合物及组合物
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
TWI795440B (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
JP2022516469A (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
TW202241413A (zh) 吡唑並喹唑啉類化合物、其製備方法及用途
EP3587418B1 (en) Inhibitors of creb binding protein (cbp)
HK40074924A (en) Inhibiting creb binding protein (cbp)
RU2803290C2 (ru) Ингибирование creb-связывающего белка (cbp)
HK40018316A (en) Inhibitors of creb binding protein (cbp)
HK40018316B (en) Inhibitors of creb binding protein (cbp)
MD3587418T2 (ro) Inhibitori ai proteinei de legare CREB (CBP)
BR122025003836A2 (pt) Composto e composição farmacêutica
EP3937940A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
EA042920B1 (ru) Ингибирование creb-связывающего белка (cbp)
EA046876B1 (ru) Ингибирование creb-связывающего белка (cbp)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201016

R150 Certificate of patent or registration of utility model

Ref document number: 6781806

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250